NASDAQ · STIM

Neuronetics, Inc.

$1.73 -$0.15 (-7.98%) 1D After hours

Key Metrics

$130.83M
Market cap
P/E · TTM
$151.64M
Revenue · TTM
−$37.11M
Net income
EPS · TTM $-0.60
Dividend yield
Free cash flow −$13.58M
Beta · 1Y 2.16
EBITDA · TTM −$26.12M
Gross margin 48.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    A material event was filed (Form 8-K).

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 20
    The stock moved +24.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 20
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +26.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • May 18
    From its Jan 29 high, the share price fell 46%.

    Peak close $2.20 on Jan 29; trough close $1.18 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -46%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$130.83M
Enterprise value$178.91M
Shares outstanding69.6M
52-wk range$0.80 – $4.85
Avg volume · 20D670.5K
Net cash −$48.08M
Book value / share$0.22
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Neuronetics, Inc.
IPO dateJun 28, 2018
Employees658

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.86
P/FCF
EV/EBITDA
EV/Sales1.18
Graham №

Profitability

Gross 48.0%
Operating -19.4%
Net -24.5%
FCF -9.0%
ROE / ROIC -181.2% · —

Financial Health

Current ratio1.67
Quick ratio1.50
Debt / equity4.62
Debt / EBITDA -2.35
Net cash −$48.08M
Working capital$18.89M

Cash Flow · TTM

Operating CF −$12.80M
Capex −$779.00K
Free cash flow −$13.58M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

-3.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings